Elevated biomarkers indicative of EBV reactivation, such as serum EBV virus capsid antigen (VCA)-IgA, have been reported as high-risk factors for NPC in several epidemiological studies (19, 20). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.